![](/images/graphics-bg.png)
Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients
Joint Authors
Sadeghi, Masoumeh
Mortazavi, Mojgan
Moghadasi, Mojdeh
Harandi, Asghar Amini
Naini, Afsoon Imami
Source
Saudi Journal of Kidney Diseases and Transplantation
Issue
Vol. 23, Issue 3 (30 Jun. 2012), pp.484-488, 5 p.
Publisher
Saudi Center for Organ Transplantation
Publication Date
2012-06-30
Country of Publication
Saudi Arabia
No. of Pages
5
Main Subjects
Topics
Abstract EN
Carnitine deficiency is a commonly observed problem in maintenance hemodialysis (MHD) patients, which results in altered metabolism of fatty acids and subsequently development of dyslipidemia.
To evaluate the effect of oral L-carnitine (LC) supplementation on lipid profile of adult MHD patients, we studied 30 of them (19 males, 11 females) who received LC supplementation of 250 mg tablets three times a day for eight weeks.
They were compared with 30 matched patients as a control group.
Serum lipid profiles were compared before and after the intervention between the two groups.
There was a significant decrease of the values of the lipid profile in the intervention group before and after carnitine supplementation including the mean values of total cholesterol (190 ± 36.8 vs.
177 ± 31.2 mg / dL), triglyceride (210 ± 64.7 vs.
190 ± 54.1 mg / dL) and LDL-cholesterol (117 ± 30.1 vs.
106 ± 26.3 mg / dL), while the values did not change siginificantly from base line in the control group.
However, the difference for HDLcholesterol in intervention group was not statistically significant.
None of the patients dropped out of the study due to drug side effects.
Oral LC supplementation (750 mg / day) is able to improve lipid profile in patients on MHD.
Further long-term studies with adequate sample size are needed to define the population of patients who would benefit more from carnitine therapy and the optimal dose and the most efficient route for administration of the drug.
American Psychological Association (APA)
Naini, Afsoon Imami& Sadeghi, Masoumeh& Mortazavi, Mojgan& Moghadasi, Mojdeh& Harandi, Asghar Amini. 2012. Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients. Saudi Journal of Kidney Diseases and Transplantation،Vol. 23, no. 3, pp.484-488.
https://search.emarefa.net/detail/BIM-297451
Modern Language Association (MLA)
Naini, Afsoon Imami…[et al.]. Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients. Saudi Journal of Kidney Diseases and Transplantation Vol. 23, no. 3 (Jun. 2012), pp.484-488.
https://search.emarefa.net/detail/BIM-297451
American Medical Association (AMA)
Naini, Afsoon Imami& Sadeghi, Masoumeh& Mortazavi, Mojgan& Moghadasi, Mojdeh& Harandi, Asghar Amini. Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients. Saudi Journal of Kidney Diseases and Transplantation. 2012. Vol. 23, no. 3, pp.484-488.
https://search.emarefa.net/detail/BIM-297451
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 487-488
Record ID
BIM-297451